首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Structure-based ligand discovery for the proteinprotein interface of chemokine receptor CXCR4
【24h】

Structure-based ligand discovery for the proteinprotein interface of chemokine receptor CXCR4

机译:趋化因子受体CXCR4蛋白接口的基于结构的配体发现

获取原文
获取原文并翻译 | 示例
       

摘要

G-protein-coupled receptors (GPCRs) are key signaling molecules and are intensely studied. Whereas GPCRs recognizing small-molecules have been successfully targeted for drug discovery, proteinrecognizing GPCRs, such as the chemokine receptors, claim few drugs or even useful small molecule reagents. This reflects both the difficulties that attend protein-protein interface inhibitor discovery, and the lack of structures for these targets. Imminent structure determination of chemokine receptor CXCR4 motivated docking screens for new ligands against a homology model and subsequently the crystal structure. More than 3 million molecules were docked against the model and then against the crystal structure; 24 and 23 high-scoring compounds from the respective screens were tested experimentally. Docking against the model yielded only one antagonist, which resembled known ligands and lacked specificity, whereas the crystal structure docking yielded four that were dissimilar to previously known scaffolds and apparently specific. Intriguingly, several were potent and relatively small, with IC_(50) values as low as 306 nM, ligand efficiencies as high as 0.36, and with efficacy in cellular chemotaxis. The potency and efficiency of these molecules has few precedents among protein-protein interface inhibitors, and supports structure-based efforts to discover leads for chemokine GPCRs.
机译:G蛋白偶联受体(GPCR)是关键的信号分子,并进行了深入研究。识别小分子的GPCR已成功地成为药物发现的目标,而蛋白质识别的GPCR(例如趋化因子受体)要求的药物很少甚至是有用的小分子试剂。这既反映了蛋白质-蛋白质界面抑制剂发现的困难,又缺乏这些靶标的结构。趋化因子受体CXCR4激发的对接筛选的结构即将确定,以针对同源模型和随后的晶体结构寻找新的配体。超过300万个分子靠着模型,然后靠着晶体结构。实验测试了来自各个筛选的24和23个高分化合物。与模型对接仅产生一种拮抗剂,该拮抗剂类似于已知的配体且缺乏特异性,而晶体结构的对接产生四种与先前已知的支架不同且明显具有特异性的拮抗剂。有趣的是,一些有效且相对较小,IC_(50)值低至306 nM,配体效率高至0.36,并且具有细胞趋化作用。这些分子的效力和效率在蛋白质-蛋白质界面抑制剂中尚无先例,并支持基于结构的研究以发现趋化因子GPCR的先导。

著录项

  • 来源
  • 作者单位

    Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;

    Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;

    Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226;

    Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada H3T 1C5,Department of Biochemistry, Universite de Montreal, Montreal, QC, Canada H3T 1J4;

    Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;

    Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;

    Centre de Recherche, Centre Hospitalier Universitaire Sainte-Justine, Montreal, QC, Canada H3T 1C5,Department of Biochemistry, Universite de Montreal, Montreal, QC, Canada H3T 1J4;

    Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;

    Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    drug design; virtual screening; promiscuous aggregation;

    机译:药物设计;虚拟筛选;混杂聚集;
  • 入库时间 2022-08-18 00:40:17

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号